PM Tracker

UnitedHealthcare's war with physician staffing firms continues. Envision Healthcare filed suit against the insurer, the physician firm announced Friday, over claim denied by the country's largest health plan.

In a heated PARP inhibitor race with GSK, AstraZeneca and Merck hope some new survival data could consolidate Lynparza’s lead in an ovarian cancer subset. But Merck can’t say the same about a potential prostate cancer expansion.

RADx is offering a total of $300 million in funding from the 2021 American Rescue Plan Act to help support not only the development of the next wave of future COVID-19 tests but also their regulatory aspirations—including both pandemic-induced emergency use authorization and full market clearance.

The European Society for Medical Oncology (ESMO) congress could have been a victory lap for Bristol Myers Squibb and Nektar Therapeutics, the moment when a bold bet delivered clinical data to upend the immuno-oncology space. Instead, the partners were left to sift through the wreckage of a failed trial that suggested bempegaldesleukin may make Opdivo less—not more—effective.

Health plans in the near future will have to start covering COVID-19 vaccines and tests that up until now had been “free.” Free is a tough act to follow.

Friday at the European Academy of Dermatology and Venereology 2022 congress, Arcutis drew the curtain back on late-stage Zoryve data in seborrheic dermatitis—a chronic inflammatory skin disease where the company is testing its drug in adults and kids ages nine years and up who have moderate-to-severe disease.

Allakos has achieved an undesired hat trick. Across three phase 3 trials, the biotech has now significantly reduced levels of a troublesome white blood cell without improving symptoms, driving it to rethink the development of an anti-Siglec-8 antibody that was once among the hottest prospects in biotech.

Baxter’s infusion pumps are in the crosshairs once again after cybersecurity software developer Rapid7 discovered multiple potential vulnerabilities in the devices.

It's been a long journey for Takeda's dengue fever vaccine, which recently won its first global approval in Indonesia. After Sanofi's dengue vaccine disaster, the company had to learn from a peer's troubles for its own development work.

How can we predict the ability of a preclinical drug to inadvertently cause or intentionally inhibit cytokine secretion and T cell activation

Today’s healthcare systems are adapting to an ever changing landscape with declining margins, M&A pressures, and the need for staff flexibility due to shortages. Read our whitepaper and dive into the way healthcare providers can digitally transform day-to-day work by streamlining costs and increasing agility by removing manual paper burdens.

This paper explores how Medical Affairs is increasingly playing a key leadership role in evidence planning and generation (part 3 in a series).

Improve your congress competitive intelligence and cut down costs by 50%

Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success.

Advanced research requires advanced tools. Our next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Simply load, scan, and insert your cartridge and come back to fully analyzed results in 75 minutes. Rethink your ELISA, with Ella.

Set a solid foundation for successful scale-up of buffer preparation.

Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals.

What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations?

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?

Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound.

How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market?

Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry.

Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays?